公开(公告)号：US10407673B2

公开(公告)日：2019-09-10

申请号：US16011622

申请日：2018-06-18

申请人： CHO Pharma Inc. ,  Academia Sinica

发明人： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC分类号： C12N9/42 ,  C12P21/00 ,  C07K16/28

摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：US10000747B2

公开(公告)日：2018-06-19

申请号：US15684897

申请日：2017-08-23

申请人： CHO Pharma Inc. ,  Academia Sinica

发明人： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC分类号： C12N9/24 ,  C12P21/00 ,  C07K16/28 ,  C12N9/42

摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：US20180057804A1

公开(公告)日：2018-03-01

申请号：US15684897

申请日：2017-08-23

申请人： CHO Pharma Inc. ,  Academia Sinica

发明人： Nan-Horng Lin ,  Lin-Ya Huang ,  Sachin S Shivatare ,  Li-Tzu Chen ,  Chi-Huey Wong ,  Chung-Yi Wu ,  Ting Cheng

IPC分类号： C12N9/42 ,  C12P21/00 ,  C07K16/28

CPC分类号： C12N9/2434 ,  C07K16/2887 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2319/21 ,  C12P21/005 ,  C12Y302/01096

摘要： A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.